Get the Stockscreener App
2.52
3.74%
0.09
Syros Pharmaceuticals Inc stock is traded at $2.52, with a volume of 68,947.
It is up +3.74% in the last 24 hours and up +28.62% over the past month.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
See More
Previous Close:
$2.43
Open:
$2.42
24h Volume:
68,947
Relative Volume:
0.17
Market Cap:
$68.15M
Revenue:
$9.94M
Net Income/Loss:
$-144.49M
P/E Ratio:
-0.4504
EPS:
-5.5956
Net Cash Flow:
$-103.90M
1W Performance:
-0.36%
1M Performance:
+28.62%
6M Performance:
-50.86%
1Y Performance:
+1.65%
1-Day Range:
$2.42
$2.59
1-Week Range:
$2.06
$2.6198
52-Week Range:
$1.43
$8.17
Syros Pharmaceuticals Inc Stock (SYRS) Company Profile
Name
Syros Pharmaceuticals Inc
Sector
Industry
Phone
617-744-1340
Address
35 CAMBRIDGE PARK DRIVE, CAMBRIDGE
Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-19 | Resumed | JMP Securities | Mkt Outperform |
| Feb-14-19 | Resumed | Oppenheimer | Outperform |
| Nov-05-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-13-18 | Reiterated | Wedbush | Outperform |
| Oct-31-17 | Resumed | Piper Jaffray | Overweight |
| Oct-23-17 | Initiated | ROTH Capital | Neutral |
| Aug-10-17 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
View All
Syros Pharmaceuticals Inc Stock (SYRS) Latest News
Syros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Sell at StockNews.com - MarketBeat
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2024 Earnings Call Transcript - MSN
Syros Pharmaceuticals, Inc. announced that it expects to receive $10 million in funding from Incyte Corporation - Marketscreener.com
Incyte Corporation and yros Pharmaceuticals Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms - Marketscreener.com
SYRSW (Syros Pharmaceuticals) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023) - Yahoo Finance
Syros Pharmaceuticals (NASDAQ:SYRS) Issues Quarterly Earnings Results - MarketBeat
Earnings call: Syros Pharmaceuticals outlines tamibarotene progress - Investing.com
Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ... - Yahoo Finance
Syros Pharmaceuticals (NASDAQ:SYRS) Earns Buy Rating from HC Wainwright - MarketBeat
Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlight - GuruFocus.com
Syros Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks
Q3 2024 Syros Pharmaceuticals Inc Earnings Call Transcript - GuruFocus.com
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update - StockTitan
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Syros Pharmaceuticals (SYRS) Loses -70.55% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Syros Pharmaceuticals (SYRS) Set to Announce Earnings on Thursday - MarketBeat
Syros Pharmaceuticals' SWOT analysis: stock outlook amid clinical setbacks - Investing.com India
Syros Pharmaceuticals' SWOT analysis: stock outlook amid clinical setbacks By Investing.com - Investing.com Australia
Piper Sandler reaffirms overweight rating and $5 PT on Syros Pharmaceuticals stock - Investing.com UK
Syros Pharmaceuticals (NASDAQ:SYRS) Upgraded by StockNews.com to "Hold" - MarketBeat
Syros Pharmaceuticals Inc (SYRS) Q2 2024 Earnings Call Highlights: Strategic Focus on ... - Yahoo Finance
Syros Pharmaceuticals (NASDAQ:SYRS) Downgraded by StockNews.com - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc.SYRS - cnhinews.com
Syros Pharmaceuticals' SWOT analysis: stock faces challenges amid clinical setbacks By Investing.com - Investing.com South Africa
Syros Pharmaceuticals' SWOT analysis: stock faces challenges amid clinical setbacks - Investing.com India
575,000 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Bought by Logos Global Management LP - Defense World
Ratios Uncovered: Breaking Down Spyre Therapeutics Inc. (SYRE)’s Trailing Twelve Months Metrics - The Dwinnex
Symphony Environmental Technologies (LON:SYM) Shares Down 13.8% - Defense World
Spyre Therapeutics Inc.’s results are impressive - US Post News
Farallon Capital Management LLC Buys Shares of 666,000 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
100,000 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Integral Health Asset Management LLC - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down to $30.17 - MarketBeat
Xilio Therapeutics Inc (XLO) rating initates by Chardan Capital Markets - Knox Daily
Itau Unibanco Holding S.A. Takes $435,000 Position in Ross Stores, Inc. (NASDAQ:ROST) - Defense World
Avoro Capital Advisors LLC Purchases Shares of 1,839,138 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Canada Pension Plan Investment Board Acquires 509,700 Shares of Symbotic Inc. (NASDAQ:SYM) - Defense World
Symbotic (NASDAQ:SYM) Shares Up 2.1% - Defense World
Arm Joins the PHLX Semiconductor Sector Index℠ (SOX℠) - sharewise
The Principles of Low-Carbon Tectonics: As Lygos, Pyran accelerate, we look at the why, the where, and the when - Biofuels Digest
Symbotic (NASDAQ:SYM) Shares Gap Up to $22.41 - Defense World
Quarterly Metrics: Quick and Current Ratios for Symbotic Inc (SYM) - The Dwinnex
Wall Street analysts’ outlook for Symbotic Inc (SYM) - SETE News
Understanding the Risks of Investing in Syros Pharmaceuticals Inc. (SYRS) - Knox Daily
Siyata Mobile Inc (SYTA) expanding its growth trajectory ahead - SETE News
What is the investor’s view on Syros Pharmaceuticals Inc. (SYRS)? - US Post News
Syros Pharmaceuticals Chief Financial Officer Acquires 407% More Stock - Simply Wall St
Syros Pharmaceuticals Inc. [SYRS] Shares Fall Approximately -60.45% Over the Year - Knox Daily
Syros Pharmaceuticals Inc.’s Shares Reel: -70.93% Quarterly Revenue Decline Amid 41.97M Market Cap - The InvestChronicle
Syros pharmaceuticals CEO buys shares worth over $160k By Investing.com - Investing.com Australia
SYRS underperforms with a -2.18 decrease in share price - US Post News
Syros Pharmaceuticals Inc Stock (SYRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Syros Pharmaceuticals Inc Stock (SYRS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Haas Jason | Chief Financial Officer |
Sep 12 '24 |
Buy |
1.68 |
45,344 |
76,006 |
124,552 |
| Chee Conley | President & CEO |
Sep 10 '24 |
Buy |
1.51 |
50,000 |
75,260 |
72,504 |
| Haas Jason | Chief Financial Officer |
Sep 10 '24 |
Buy |
1.55 |
35,363 |
54,788 |
59,915 |
| Haas Jason | Chief Financial Officer |
Sep 11 '24 |
Buy |
1.58 |
19,293 |
30,446 |
79,208 |
| Young Richard A | Director |
Jun 28 '24 |
Sale |
5.12 |
34,837 |
178,365 |
8,000 |
| Roth David | Chief Medical Officer |
Apr 03 '24 |
Sale |
4.95 |
10,451 |
51,732 |
0 |
| Roth David | Chief Medical Officer |
Apr 02 '24 |
Sale |
4.98 |
150 |
747 |
10,451 |
| AKKARAJU SRINIVAS | Director |
Dec 21 '23 |
Buy |
4.42 |
904,977 |
3,999,998 |
1,786,427 |
| Roth David | Chief Medical Officer |
Dec 12 '23 |
Sale |
4.95 |
6,287 |
31,121 |
0 |
| Roth David | Chief Medical Officer |
Dec 06 '23 |
Sale |
3.95 |
6,287 |
24,834 |
6,287 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):